Health

U.S. Measles Toll Exceeds 5,400 Cases and 10 Deaths as FDA Mandates Class-Wide Vision Loss Warnings on Popular GLP-1 Medications

Federal public health authorities reported on Monday that the national measles outbreak has climbed past 5,400 confirmed infections across 38 states, while the FDA announced mandatory boxed warnings on blockbuster GLP-1 weight-loss drugs regarding rare but irreversible non-arteritic anterior ischemic optic neuropathy (NAION).

November 16, 2026|6 min read
U.S. Measles Toll Exceeds 5,400 Cases and 10 Deaths as FDA Mandates Class-Wide Vision Loss Warnings on Popular GLP-1 Medications

ATLANTA — The United States public health establishment faced a dual front of critical medical challenges on Monday as the Centers for Disease Control and Prevention reported that the ongoing nationwide measles outbreak has officially surpassed 5,400 laboratory-confirmed cases, while the Food and Drug Administration issued an urgent class-wide safety alert for millions of patients taking GLP-1 receptor agonist medications.

According to the CDC's updated epidemiological bulletin, measles infections have now been detected across 38 states, with severe localized clusters driving pediatric hospitalizations in Texas, Florida, Ohio, and Arizona. Public health officials confirmed two additional fatalities over the weekend—an unvaccinated infant in suburban Houston and an immunocompromised adult in Cincinnati—bringing the nationwide death toll from the resurgence to ten, the highest domestic casualty figure recorded from the vaccine-preventable virus in three decades.

The Pan American Health Organization (PAHO) announced that an international panel of epidemiological observers has initiated on-site technical consultations with federal health leaders in Atlanta and Washington to assess whether the United States' historic 2000 measles eradication status must be formally suspended. Health experts attributed the widespread transmission to falling kindergarten MMR vaccination rates, which have slipped below 92 percent nationally and dropped under 85 percent in several rural school districts.

Simultaneously, FDA Commissioner Robert Califf announced a significant regulatory action mandating updated boxed safety warnings across all GLP-1 receptor agonist therapies—including popular semaglutide and tirzepatide formulations prescribed for type 2 diabetes and chronic obesity. The FDA's directive follows comprehensive multi-center cohort studies linking the medication class to a small but statistically significant increase in the incidence of non-arteritic anterior ischemic optic neuropathy (NAION), a condition characterized by sudden, painless vision loss resulting from insufficient blood flow to the optic nerve head.

'While these medications have delivered transformative benefits for millions of individuals managing metabolic disease, the scientific evidence regarding optic nerve ischemic events demands clear, transparent clinical labeling,' Dr. Califf emphasized. The FDA instructed prescribing physicians to perform baseline ocular health screenings and advised patients experiencing acute changes in visual acuity to discontinue treatment immediately and seek neuro-ophthalmic evaluation.

Related Coverage